The Role of Canine Models of Human Cancer: Overcoming Drug Resistance Through a Transdisciplinary “One Health, One Medicine” Approach

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

Ballard, P., Yates, J. W. T., Yang, Z., Kim, D.-W., Yang, J. C.-H., Cantarini, M., Pickup, K., Jordan, A., Hickey, M., Grist, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0399 · Cited by 718

Spontaneous tumors in dogs and cats: Models for the study of cancer biology and treatment

MacEwen, E. G. (1990) · Cancer and Metastasis Reviews · doi:10.1007/bf00046339 · Cited by 393

Functional Multidrug Resistance Protein (MRP1) Lacking the N-terminal Transmembrane Domain

Bakos, É., Evers, R., Szakács, G., Tusnády, G., Welker, E., Szabó, K., de Haas, M., van Deemter, L., Borst, P., Váradi, A., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.48.32167 · Cited by 326

Doxorubicin-loaded iron oxide nanoparticles for glioblastoma therapy: a combinational approach for enhanced delivery of nanoparticles

Norouzi, M., Yathindranath, V., Thliveris, J. A., Kopec, B. M., Siahaan, T. J., & Miller, D. W. (2020) · Scientific Reports · doi:10.1038/s41598-020-68017-y · Cited by 295

Animal models and therapeutic molecular targets of cancer: utility and limitations

Cekanova, M., & Rathore, K. (2014) · Drug Design, Development and Therapy · doi:10.2147/dddt.s49584 · Cited by 274

Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs

Colclough, N., Chen, K., Johnström, P., Strittmatter, N., Yan, Y., Wrigley, G. L., Schou, M., Goodwin, R. J. A., Varnäs, K., Adua, S. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1871 · Cited by 244

Cytochrome P450 enzymes: Novel options for cancer therapeutics

McFadyen, M. C. E., Melvin, W. T., & Murray, G. I. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.363.3.3 · Cited by 242

Dogs as a Model for Cancer

Gardner, H. L., Fenger, J. M., & London, C. A. (2016) · Annual Review of Animal Biosciences · doi:10.1146/annurev-animal-022114-110911 · Cited by 215

MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin

Roulet, A., Puel, O., Gesta, S., Lepage, J.-F., Drag, M. D., Soll, M. D., Alvinerie, M., & Pineau, T. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02955-2 · Cited by 174

Canine cancer immunotherapy studies: linking mouse and human

Park, J. S., Withers, S. S., Modiano, J. F., Kent, M. S., Chen, M., Luna, J. I., Culp, W. T. N., Sparger, E. E., Rebhun, R. B., Monjazeb, A. M., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0200-7 · Cited by 121

Comparative oncology: overcoming human cancer through companion animal studies

Oh, J. H., & Cho, J. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00977-3 · Cited by 119

The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors

Lin, T., Bear, M. D., Du, Z., Foley, K. P., Ying, W., Barsoum, J., & London, C. A. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2008.05.001 · Cited by 112

Gene expression profiling of canine osteosarcoma reveals genes associated with short and long survival times

Selvarajah, G. T., Kirpensteijn, J., van Wolferen, M. E., Rao, N., Fieten, H., & Mol, J. A. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-72 · Cited by 98

Canine Cytochrome P-450 Pharmacogenetics

Court, M. H. (2013) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2013.05.001 · Cited by 93

Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System

Parrish, K. E., Cen, L., Murray, J., Calligaris, D., Kizilbash, S. H., Mittapalli, R. K., Carlson, B. L., Schroeder, M. A., Sludden, J., Boddy, A. V., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0553 · Cited by 93

Hedgehog Pathway Inhibitor HhAntag691 Is a Potent Inhibitor of ABCG2/BCRP and ABCB1/Pgp

Zhang, Y., Laterra, J., & Pomper, M. G. (2009) · Neoplasia · doi:10.1593/neo.81264 · Cited by 76

The Expression of P-Glycoprotein in Canine Lymphoma and Its Association with Multidrug Resistance

Moore, A. S., Leveille, C. R., Reimann, K. A., Hsing, S., & Arias, I. M. (1995) · Cancer Investigation · doi:10.3109/07357909509024910 · Cited by 73

In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors

Barbieri, F., Thellung, S., Ratto, A., Carra, E., Marini, V., Fucile, C., Bajetto, A., Pattarozzi, A., Würth, R., Gatti, M., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1235-8 · Cited by 61

Global Gene Expression Analysis of Canine Osteosarcoma Stem Cells Reveals a Novel Role for COX-2 in Tumour Initiation

Pang, L. Y., Gatenby, E. L., Kamida, A., Whitelaw, B., Hupp, T. R., & Argyle, D. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0083144 · Cited by 58

NEMO-Binding Domain Peptide Inhibits Constitutive NF-κB Activity and Reduces Tumor Burden in a Canine Model of Relapsed, Refractory Diffuse Large B-Cell Lymphoma

Gaurnier-Hausser, A., Patel, R. T., Baldwin, A. S., May, M. J., & Mason, N. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3310 · Cited by 57

Expression profiling in canine osteosarcoma: identification of biomarkers and pathways associated with outcome

O’Donoghue, L. E., Ptitsyn, A. A., Kamstock, D. A., Siebert, J., Thomas, R. S., & Duval, D. L. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-506 · Cited by 56

Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma

Salphati, L., Alicke, B., Heffron, T. P., Shahidi-Latham, S. K., Nishimura, M. C., Cao, T. C., Carano, R. A. D., Cheong, J., Greve, J. M., Koeppen, H., et al. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.071423 · Cited by 53

4-Anilino-2-pyridylquinazolines and -pyrimidines as Highly Potent and Nontoxic Inhibitors of Breast Cancer Resistance Protein (ABCG2)

Krapf, M. K., Gallus, J., & Wiese, M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00441 · Cited by 51

Doxorubicin induced expression of P-glycoprotein in a canine osteosarcoma cell line

Mealey, K. L., Barhoumi, R., Rogers, K. S., & Kochevar, D. T. (1998) · Cancer Letters · doi:10.1016/s0304-3835(98)00004-4 · Cited by 45

Saturable Active Efflux by P-Glycoprotein and Breast Cancer Resistance Protein at the Blood-Brain Barrier Leads to Nonlinear Distribution of Elacridar to the Central Nervous System

Sane, R., Agarwal, S., Mittapalli, R. K., et al. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.199786 · Cited by 44

EGFR, HER-2 and KRAS in Canine Gastric Epithelial Tumors: A Potential Human Model?

Terragni, R., Gardini, A. C., Sabattini, S., Bettini, G., Amadori, D., Talamonti, C., Vignoli, M., Capelli, L., Saunders, J. H., Ricci, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085388 · Cited by 44

Mechanisms of Drug Resistance in Veterinary Oncology— A Review with an Emphasis on Canine Lymphoma

Zandvliet, M. M. J. M., & Teske, E. (2015) · Veterinary Sciences · doi:10.3390/vetsci2030150 · Cited by 42

Multi-drug resistance in a canine lymphoid cell line due to increased P-glycoprotein expression, a potential model for drug-resistant canine lymphoma

Zandvliet, M. M. J. M., Teske, E., & Schrickx, J. A. (2014) · Toxicology in Vitro · doi:10.1016/j.tiv.2014.06.004 · Cited by 41

HES1, a target of Notch signaling, is elevated in canine osteosarcoma, but reduced in the most aggressive tumors

Dailey, D. D., Anfinsen, K. P., Pfaff, L. E., Ehrhart, E. J., Charles, J. B., Bønsdorff, T. B., Thamm, D. H., Powers, B. E., Jónasdóttir, T. J., & Duval, D. L. (2013) · BMC Veterinary Research · doi:10.1186/1746-6148-9-130 · Cited by 41

In vitro and in vivo characterization of stem-like cells from canine osteosarcoma and assessment of drug sensitivity

Gatti, M., Solari, A., Pattarozzi, A., Campanella, C., Thellung, S., Maniscalco, L., Maria, R. D., Würth, R., Corsaro, A., Bajetto, A., et al. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.01.002 · Cited by 39

Conduct, Oversight, and Ethical Considerations of Clinical Trials in Companion Animals with Cancer: Report of a Workshop on Best Practice Recommendations

Page, R. L., Baneux, P. J. R., Vail, D. M., Duda, L., Olson, P., Anestidou, L., Dybdal, N. O., Golab, G. C., Shelton, W., Salgaller, M. L., et al. (2016) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.13916 · Cited by 38

Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer

Cronise, K. E., Hernandez, B. G., Gustafson, D. L., & Duval, D. L. (2019) · Molecular Pharmacology · doi:10.1124/mol.119.115808 · Cited by 38

Hemangiosarcoma and its cancer stem cell subpopulation are effectively killed by a toxin targeted through epidermal growth factor and urokinase receptors

Schappa, J. T., Frantz, A. M., Gorden, B. H., Dickerson, E. B., Vallera, D. A., & Modiano, J. F. (2013) · International Journal of Cancer · doi:10.1002/ijc.28187 · Cited by 37

Mechanisms of tumour resistance against chemotherapeutic agents in veterinary oncology

Klopfleisch, R., Kohn, B., & Gruber, A. D. (2015) · The Veterinary Journal · doi:10.1016/j.tvjl.2015.06.015 · Cited by 36

Breaking barriers: we need a multidisciplinary approach to tackle cancer drug resistance

Ingham, J., Ruan, J.-L., & Coelho, M. A. (2025) · BJC Reports · doi:10.1038/s44276-025-00129-2 · Cited by 36

Design, Biological Evaluation, and Molecular Modeling of Tetrahydroisoquinoline Derivatives: Discovery of A Potent P-Glycoprotein Ligand Overcoming Multidrug Resistance in Cancer Stem Cells

Riganti, C., Contino, M., Guglielmo, S., Perrone, M. G., Salaroglio, I. C., Milosevic, V., Giampietro, R., Leonetti, F., Rolando, B., Lazzarato, L., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01655 · Cited by 33

Canine models of human cancer: Bridging the gap to improve precision medicine

Nance, R. L., Sajib, A. M., & Smith, B. F. (2022) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.12.003 · Cited by 33

Crown ethers reverse P-glycoprotein-mediated multidrug resistance in cancer cells

Guberović, I., Marjanović, M., Mioč, M., Ester, K., Martin‐Kleiner, I., Ramljak, T. Š., Mlinarić‐Majerski, K., & Kralj, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-32770-y · Cited by 32

Review: NF-kB activation in canine cancer

Schlein, L. J., & Thamm, D. H. (2022) · Veterinary Pathology · doi:10.1177/03009858221092017 · Cited by 32

FLT3 mutations in canine acute lymphocytic leukemia

Suter, S. E., Small, G. W., Seiser, E., Thomas, R. J., Breen, M., & Richards, K. L. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-38 · Cited by 31

Masitinib reverses doxorubicin resistance in canine lymphoid cells by inhibiting the function of P ‐glycoprotein

Zandvliet, M. M. J. M., Teske, E., Chapuis, T., Fink‐Gremmels, J., & Schrickx, J. A. (2013) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.12039 · Cited by 31

The Effect of a Histone Deacetylase Inhibitor (AR‐42) on Canine Prostate Cancer Growth and Metastasis

Elshafae, S. M., Kohart, N. A., Altstadt, L. A., Dirksen, W. P., & Rosol, T. J. (2017) · The Prostate · doi:10.1002/pros.23318 · Cited by 31

Clinical, Pathological, and Ethical Considerations for the Conduct of Clinical Trials in Dogs with Naturally Occurring Cancer: A Comparative Approach to Accelerate Translational Drug Development

Regan, D. P., Garcia, K. D., & Thamm, D. H. (2018) · ILAR Journal · doi:10.1093/ilar/ily019 · Cited by 30

Brivanib Exhibits Potential for Pharmacokinetic Drug–Drug Interactions and the Modulation of Multidrug Resistance through the Inhibition of Human ABCG2 Drug Efflux Transporter and CYP450 Biotransformation Enzymes

Hofman, J., Sorf, A., Vagiannis, D., Sucha, S., Kammerer, S., Küpper, J., Chen, S., Guo, L., Čečková, M., & Štaud, F. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00361 · Cited by 28

On the need for integrating cancer into the One Health perspective

Dujon, A. M., Brown, J. S., Destoumieux‐Garzón, D., Vittecoq, M., Hamede, R., Tasiemski, A., Boutry, J., Tissot, S., Alix‐Panabières, C., Pujol, P., et al. (2021) · Evolutionary Applications · doi:10.1111/eva.13303 · Cited by 28

Advancing Veterinary Oncology: Next-Generation Diagnostics for Early Cancer Detection and Clinical Implementation

Alshammari, A. H., Oshiro, T., Ungkulpasvich, U., Yamaguchi, J., Morishita, M., Khdair, S. A., Hatakeyama, H., Hirotsu, T., & di Luccio, E. (2025) · Animals · doi:10.3390/ani15030389 · Cited by 27

Advances of Osteosarcoma Models for Drug Discovery and Precision Medicine

Tan, L., Wang, Y., Hu, X., Du, G., Tang, X., & Min, L. (2023) · Biomolecules · doi:10.3390/biom13091362 · Cited by 25

Optimization of canine CD20 chimeric antigen receptor T cell manufacturing and in vitro cytotoxic activity against B‐cell lymphoma

Sakai, O., Igase, M., & Mizuno, T. (2020) · Veterinary and Comparative Oncology · doi:10.1111/vco.12602 · Cited by 22

The Use of Chemotherapy to Prolong the Life of Dogs Suffering from Cancer: The Ethical Dilemma

Stephens, T. W. (2019) · Animals · doi:10.3390/ani9070441 · Cited by 21

Development of multidrug resistance in a canine lymphoma cell line

Uozurmi, K., NAKAICHI, M., Yamamoto, Y., Satoshi, U. N. E., & TAURA, Y. (2005) · Research in Veterinary Science · doi:10.1016/j.rvsc.2004.09.012 · Cited by 20

Isobavachalcone as an Active Membrane Perturbing Agent and Inhibitor of ABCB1 Multidrug Transporter

Palko-Łabuz, A., Błaszczyk, M., Środa-Pomianek, K., & Wesołowska, O. (2021) · Molecules · doi:10.3390/molecules26154637 · Cited by 20

BMI1 Is Expressed in Canine Osteosarcoma and Contributes to Cell Growth and Chemotherapy Resistance

Shahi, M. H., York, D. S., Gandour‐Edwards, R. F., Withers, S. S., Holt, R., & Rebhun, R. B. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131006 · Cited by 19

A Novel Canine Mammary Cancer Cell Line: Preliminary Identification and Utilization for Drug Screening Studies

Li, R., Wu, H., Sun, Y., Zhu, J., Tang, J., Kuang, Y., & Li, G. (2021) · Frontiers in Veterinary Science · doi:10.3389/fvets.2021.665906 · Cited by 19

Identification of Illness Uncertainty in Veterinary Oncology: Implications for Service

Stoewen, D. L., Coe, J. B., MacMartin, C., STONE, E. A., & Dewey, C. E. (2019) · Frontiers in Veterinary Science · doi:10.3389/fvets.2019.00147 · Cited by 18

How companion animals contribute to the fight against cancer in humans.

Thamm, D. H., & DOW, S. W. (2009) · PubMed · Cited by 16

Precision Medicine in Veterinary Science

Chon, E., Hendricks, W. P. D., White, M. E., Rodrigues, L., Haworth, D., & Post, G. S. (2024) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2023.12.006 · Cited by 15

HZ08 Reverse P-Glycoprotein Mediated Multidrug Resistance In Vitro and In Vivo

Hu, Z., Zhou, Z., Hu, Y., Wu, J., Li, Y., & Huang, W. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116886 · Cited by 13

Expression of asparagine synthetase predictsin vitroresponse to l -asparaginase in canine lymphoid cell lines

Smallwood, T., Small, G. W., Suter, S. E., & Richards, K. L. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.842980 · Cited by 12

Celastrol Inhibits Canine Mammary Tumor Cells by Inducing Apoptosis via the Caspase Pathway

Ou, G., Jiang, X., Gao, A., Li, X., Lin, Z., & Pei, S. (2022) · Frontiers in Veterinary Science · doi:10.3389/fvets.2021.801407 · Cited by 11

Comparative characterization of stem cell marker expression, metabolic activity and resistance to doxorubicin in adherent and spheroid cells derived from the canine prostate adenocarcinoma cell line CT1258.

Liu, W., Moulay, M., Willenbrock, S., Roolf, C., Junghanß, C., Ngenazahayo, A., Nolte, I. J. A., & Escobar, H. M. (2015) · PubMed · Cited by 10

Activation of the Anaphase Promoting Complex Reverses Multiple Drug Resistant Cancer in a Canine Model of Multiple Drug Resistant Lymphoma

Arnason, T., MacDonald‐Dickinson, V., Davies, J. F., Lobanova, L., Gaunt, C., Trost, B., Waldner, M., Baldwin, P., Borrowman, D., Marwood, H., et al. (2022) · Cancers · doi:10.3390/cancers14174215 · Cited by 10

Epigenetic Alterations in Canine Malignant Lymphoma: Future and Clinical Outcomes

Montaner-Angoiti, E., Marín‐García, P. J., & Llobat, L. (2023) · Animals · doi:10.3390/ani13030468 · Cited by 10

Anti-neoplastic effects of topoisomerase inhibitors in canine mammary carcinoma, melanoma, and osteosarcoma cell lines.

Ong, S. M., Yamamoto, H., Saeki, K., Tanaka, Y., Yoshitake, R., Nishimura, R., & Nakagawa, T. (2017) · PubMed · doi:10.14943/jjvr.65.1.17 · Cited by 9

Dasatinib inhibition of cSRC prevents the migration and metastasis of canine mammary cancer cells with enhanced Wnt and HER signalling

Timmermans‐Sprang, E. P. M., Mestemaker, H. M., Steenlage, R. R., & Mol, J. A. (2019) · Veterinary and Comparative Oncology · doi:10.1111/vco.12490 · Cited by 9

SOX2 Expression in Canine Neoplasia

Miranda, I. C., & Miller, A. D. (2020) · Veterinary Pathology · doi:10.1177/0300985820960130 · Cited by 9

ANIMAL SENTINELS AND CANCER REGISTRIES: STATE OF THE ART AND NEW PERSPECTIVES

Biase, D. D., Baldassarre, V., Piegari, G., Rosato, G., Caputo, V., Pompameo, M., Sarnelli, P., Russo, V., D’Angelo, D., & Papparella, S. (2023) · Annals of Research in Oncology · doi:10.48286/aro.2023.61 · Cited by 9

Single-Nuclei Multiome (ATAC + Gene Expression) Sequencing of a Primary Canine Osteosarcoma Elucidates Intra-Tumoral Heterogeneity and Characterizes the Tumor Microenvironment

Nance, R. L., Wang, X., Sandey, M., Matz, B. M., Thomas, A., & Smith, B. F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216365 · Cited by 8

Canine osteosarcoma cells exhibit resistance to aurora kinase inhibitors

Cannon, C. M., Pozniak, J., Scott, M. C., Ito, D., Gorden, B. H., Graef, A. J., & Modiano, J. F. (2013) · Veterinary and Comparative Oncology · doi:10.1111/vco.12018 · Cited by 7

Inhibition of canine telomerase in vitro and in vivo using RNAi: Further development of a natural canine model for telomerase-based cancer therapies

Lund, J. R., Paoloni, M., Kurzman, I. D., Padilla, M. L., & Argyle, D. J. (2007) · The Veterinary Journal · doi:10.1016/j.tvjl.2007.09.015 · Cited by 7

Transcriptomic Analysis of Canine Osteosarcoma from a Precision Medicine Perspective Reveals Limitations of Differential Gene Expression Studies

Nance, R. L., Cooper, S. J., Starenki, D., Wang, X., Matz, B. M., Lindley, S. S., Smith, A. N., Smith, A. A., Bergman, N. S., Sandey, M., et al. (2022) · Genes · doi:10.3390/genes13040680 · Cited by 6

One Health in the EU: The Next Future?

Coli, F., & Schebesta, H. (2023) · Socio-Environmental Systems Modeling · doi:10.15166/2499-8249/652 · Cited by 6

Sequence and structural analysis of the presumed downstream promoter of the canine mdr1 gene

Mealey, K. L., & Bentjen, S. A. (2003) · Veterinary and Comparative Oncology · doi:10.1046/j.1476-5829.2003.00002.x · Cited by 5

Detection and significance of glutathione-S-transferase pi in osteogenic tumors of dogs

Shoieb, A. M., & Hahn, K. A. (1997) · International Journal of Oncology · doi:10.3892/ijo.10.3.635 · Cited by 5

Assessment of Canonical NF-κB Activity in Canine Diffuse Large B-Cell Lymphoma

Gaurnier-Hausser, A., & Mason, N. J. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2422-6_29 · Cited by 5

Cross-Species Comparison of the Pan-RAF Inhibitor LY3009120’s Anti-Tumor Effects in Equine, Canine, and Human Malignant Melanoma Cell Lines

Yu, G., Packeiser, E., Wendt, S., Sekora, A., Cavalleri, J. V., Pratscher, B., Alammar, M., Hühns, M., Brenig, B., Junghanß, C., et al. (2024) · Genes · doi:10.3390/genes15020202 · Cited by 5

Collaboration between human and veterinary medicine in Europe: a systematic review

Torre, G. L., Barbato, D., Colamesta, V., Lia, L., Lombardi, A., Cacchio, D., Villari, P., & Giusti, M. (2018) · European Journal of Public Health · doi:10.1093/eurpub/cky212.435 · Cited by 2

Expression and therapeutic targeting of BMI1 in canine gliomas

Al‐Nadaf, S., Peacott‐Ricardos, K. S., Dickinson, P. J., Rebhun, R. B., & York, D. S. (2022) · Veterinary and Comparative Oncology · doi:10.1111/vco.12852 · Cited by 2

The EphA2 Receptor Regulates Invasiveness and Drug Sensitivity in Canine and Human Osteosarcoma Cells

Harris, E. D., Sharpe, J. C., Strozen, T. G., Abdi, S., Kliewer, M., Sanchez, M. G., Hogan, N., MacDonald‐Dickinson, V., Vizeacoumar, F. J., & Toosi, B. M. (2024) · Cells · doi:10.3390/cells13141201 · Cited by 2

Collaboration between human and veterinary medicine in Europe: a systematic review

Torre, G. L., Barbato, D., Colamesta, V., Lia, L., Lombardi, A., Cacchio, D., Villari, P., & Giusti, M. (2018) · European Journal of Public Health · doi:10.1093/eurpub/cky213.435 · Cited by 1

L’approccio One Health nella legislazione europea sugli animali: orientamenti e prospettive

Leone, L. (2025) · CINECA IRIS Institutial research information system (University of Pisa) · Cited by 1

Phage therapy in oncology: opportunities for cancer prevention and treatment

Mutalik, V. K., Inman, J. L., Chang, H., Arkin, A., & Mao, J.-H. (2026) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2026.02.001 · Cited by 7